| A Long-Term Extension Study of Nusinersen (BIIB058) Administered at Higher Doses in Participants With Spinal Muscular Atrophy Who Previously Participated in an Investigational Study With Nusinersen |
Ongoing |
Nusinersen (Spinraza) |
3 |
232SM302 |
King Faisal Specialist Hospital and Research Center (Riyadh),King Fahad Specialist Hospital (Dammam),King Abdulaziz Medical City NG (Jeddah) |
| A randomized double-blind placebo-controlled parallel group study assessing the efficacy and safety of dupilumab in patients with Allergic Fungal Rhinosinusitis (AFRS) |
Ongoing |
Dupilumab |
3 |
EFC16724 |
King Khalid University Hospital (Riyadh),King Faisal Specialist Hospital and Research Center (Riyadh) |
| Treatment of Cardio Vascular Disease with low dose Rivaroxaban in Advanced Chronic Kidney Disease(TRACK) |
Ongoing |
Rivaroxaban |
3 |
SCT21R/008/10 |
King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah),King Khalid University Hospital (Riyadh) |
| A PHASE 2A, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL PF-06651600 AND PF 06700841 AS INDUCTION AND OPEN LABEL EXTENSION TREATMENT IN SUBJECTS WITH MODERATE TO SEVERE CROHN’S DISEASE |
Completed |
PF-06651600 |
2a |
B7981007 |
NGHA-R,KKUH, King Abdulaziz Medical City NG (Jeddah) |
| A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) |
Ongoing |
BI 1015550 |
3 |
1305-0023 |
King Faisal Specialist Hospital and Research Center (Riyadh) , King Abdulaziz Medical City NG (Riyadh) , King Abdulaziz University Hospital (Jeddah),King Fahad Specialist Hospital (Dammam) |
| A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants with Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST) |
Ongoing |
BIIB059 |
2/3 |
230LE301 |
King Faisal Specialist Hospital and Research Center (Riyadh) , King Khalid University Hospital (Riyadh) |
| Multicenter, open-label, study to evaluate safety,tolerability, pharmacokinetics and, pharmacodynamics of LCZ696 followed by a 52-week randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared with enalapril in pediatric patients from1 month to < 18 years of age with heart failure due to systemic left ventricle systolic dysfunction) |
Completed |
Entresto |
3 |
CLCZ696B2319 |
KFSH&RC-R , KFSH-D |
| An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease |
Completed |
ribociclib / letrozole |
3b |
CLEE011A2404 |
NGHA-R , KFSH&RC-R , KFSH , KAMC , NGHA-J , KFMC |
| " A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer" |
Completed |
LEE011 (Ribociclib) |
3 |
CLEE011E2301 |
KKUH , KFSH & RC-R , NGHA-R , NGHA-J |
| A Retrospective Observational Non-Interventional Study (NIS) to assess Patient Characteristics and Healthcare Resource Use (HCRU) among COVID-19 Patients Receiving Treatment with Nirmatrelvir; Ritonavir (PAXLOVIDTM) in the Kingdom of Saudi Arabia (KSA) |
Ongoing |
Paxlovid |
4 |
C4671054 |
King Faisal Specialist Hospital and Research Center (Riyadh) , King Faisal Specialist Hospital and Research Center (Jeddah) , King Abdulaziz Medical City NG (Riyadh) , King Abdulaziz Medical City NG (Riyadh) |
